Results 121 to 130 of about 17,793 (220)
A case report of deglutition triggered atrial fibrillation in a patient with Laing distal myopathy. [PDF]
Alvarez CK, Swales H, Kluger J.
europepmc +1 more source
Miyoshi Myopathy: A Case Report [PDF]
We report a 25-year-old man who manifested typical symptoms of Miyoshi myopathy with brief review of literatures. Miyoshi myopathy is a rare distal myopathy which develops between 15 and 30 years of age and starts from the distal muscles, especially ...
최영철
core
Laing early-onset distal myopathy in a Belgian family
We report the first Belgian family with Laing early-onset distal myopathy (MPD1). The proposita started limping at age 7. Later, there was severe weakness of proximal and distal muscles, including neck flexors.
Udd, Bjarne +9 more
core +1 more source
A novel frameshift ACTN2 variant causes a rare adult-onset distal myopathy with multi-minicores. [PDF]
Chen L, Chen DF, Dong HL, Liu GL, Wu ZY.
europepmc +1 more source
Out-of-Frame Mutations in <i>ACTN2</i> Last Exon Cause a Dominant Distal Myopathy With Facial Weakness. [PDF]
Savarese M +14 more
europepmc +1 more source
Dynamics of T-Cell Intracellular Antigen 1-Dependent Stress Granules in Proteostasis and Welander Distal Myopathy under Oxidative Stress. [PDF]
Fernández-Gómez A +2 more
europepmc +1 more source
Early onset chromosome 14-linked distal myopathy (Laing)
A dominantly inherited form of distal myopathy with onset in early childhood was first reported in a 4-generation Australian family in 1995. In the present report we provide further information on the clinical phenotype and natural history of this ...
Mastaglia, F.L. +6 more
core
Laing early onset distal myopathy: slow mysosin defect with variable abnormalities on muscle biopsy
Background: Laing early onset distal myopathy (MPD1) is an autosomal dominant myopathy caused by mutations within the slow skeletal muscle fibre myosin heavy chain gene, MYH7.
Mastaglia, F.L. +14 more
core +1 more source
The myosin inhibitor mavacamten has transformed the management of obstructive hypertrophic cardiomyopathy (HCM) by targeting myosin ATPase activity to mitigate cardiac hypercontractility.
Julius Bogomolovas, Ju Chen
doaj +1 more source

